Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Treating Locally Advanced Rectal Cancer

November 21st 2018

Maintaining Wellness After Treatment

November 21st 2018

Optimal Duration of Therapy for Stage III Colon Cancer

November 21st 2018

Treatment Options for High-Risk Stage II Colon Cancer

November 21st 2018

Efficacy of Adjuvant Therapy in Stage II Colon Cancer

November 21st 2018

Current Role of Adjuvant Therapy for Colon Cancer

November 21st 2018

Dr. Cercek on Chemotherapy Resistance in dMMR Rectal Cancer

November 20th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.

Dabrafenib Plus Trametinib Demonstrates Activity in GI Cancers

November 17th 2018

The combination of dabrafenib and trametinib led to encouraging responses in patients with rare, incurable cancer of the digestive tract.

Novel Agent Active Across Heavily Pretreated HER2+ Tumors

November 17th 2018

The novel bispecific antibody ZW25 induced a disease control rate of 82% in heavily pretreated patients across several HER2-positive tumor types, according to phase I study results presented at the 2018 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.

Dr. Overman on the Combination of Atezolizumab and Bevacizumab in HCC

November 17th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in hepatocellular carcinoma (HCC).

Novel Drug Combination Shows Early Activity in Microsatellite Stable CRC

November 17th 2018

Pixatimod (PG545) in combination with the PD-1 inhibitor nivolumab (Opdivo) may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.

Dr. Berk on Immunotherapy Options for Patients With Colon Cancer

November 17th 2018

Seth Berk, MD, section chief of gastrointestinal hematology/oncology at Virtua Memorial Hospital, discusses the use of immunotherapy in colon cancer.

Future Research and the Clinical Management of mCRC

November 16th 2018

Additional Considerations for Targeted Therapy in mCRC

November 16th 2018

Tumor Sidedness and Treatment Considerations in mCRC

November 16th 2018

RAS Mutation Testing in mCRC

November 16th 2018

Frontline Management of Newly Diagnosed mCRC

November 16th 2018

Dr. Benson on the Clinical Utility of cfDNA in Colorectal Cancer

November 16th 2018

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the clinical utility of cell-free DNA (cfDNA) in guiding treatment decisions for patients with colorectal cancer (CRC).

Rationale for Pembrolizumab Plus mFOLFOX6 in Advanced CRC

November 15th 2018

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.

Dr. Iqbal on HER2-Driven Gastric Cancer

November 15th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the treatment of patients with HER2-driven gastric cancer.